JBT-101 in Systemic Lupus Erythematosus (SLE)



Status:Recruiting
Conditions:Lupus
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:18 - 70
Updated:3/16/2019
Start Date:December 21, 2017
End Date:February 2020

Use our guide to learn which trials are right for you!

A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of JBT-101 in Systemic Lupus Erythematosus (ALE09)

The objective of this study is to evaluate the efficacy, safety, and tolerability of JBT-101
(also known as lenabasum) in systemic lupus erythematosus (SLE).

- One hundred adults with active joint disease and at least moderate pain will be enrolled
in this study to evaluate treatment of their systemic lupus erythematosus (SLE) with
JBT-101. JBT-101 is a synthetic endocannabinoid receptor type 2 (CB2) agonist and an
activator of the body's normal processes, to resolve innate immune responses without
immunosuppression.

- Participants will receive 2 doses of JBT-101 by mouth (three groups of varying doses)
or, placebo, for 84 days and will continue to be followed for an additional 28 days.
Participant visits to assess endpoints occur on Day 1, then every 2 weeks twice, then
every 4 weeks three times, for a total of six visits.

- The change in maximum daily pain Numerical Rating Scale (NRS) score from Baseline (Visit
1) will be assessed at every visit.


Inclusion Criteria:

- Fulfills the updated American College of Rheumatology (ACR) 1982 Revised Criteria for
the Classification of Systemic Lupus Erythematosus;

- At least 3 months of treatment with an anti-malarial drug such as hydroxychloroquine
or a history of intolerance, contraindication, or unwillingness to take an
anti-malarial drug;

- Meets the Safety of Estrogen in Lupus: National Assessment (SELENA) Systemic Lupus
Erythematosus Disease Activity Index (SLEDAI) definition of arthritis (Petri et al.,
1999) or mild/moderate arthritis or tendonitis scored as a BILAG B on the updated
BILAG 2004;

- Seven-day average of maximum of daily pain Numerical Rating Scale (NRS) scores ≥ 4 out
of 10;

- Overlap with polymyositis, systemic sclerosis, Sjögren's syndrome, or rheumatoid
arthritis is allowed, if, in the site investigator's judgment, the predominant
clinical features are those of Systemic Lupus Erythematosus (SLE);

- Not expected by the site investigator to require a change in potential disease-
modifying treatments for SLE from Screening through Visit 6 (Day 112);

- Willing to not start nor stop any Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or
potential disease-modifying medications or supplements for SLE from Screening through
Visit 6 (Day 112), unless a change is recommended by the site investigator or other
treating physicians;

- Willing not to use any legal or illegal cannabinoids, including Food and Drug
Administration (FDA)-approved cannabinoids or cannabinoid-mimic drugs, or any illegal
substance of abuse from Screening through Visit 6 (Day 112);

- If a woman of child-bearing potential, willing to use one of the highly effective
(failure rate < 1% per year) birth control method from Screening through Visit 6 (Day
112) or for 28 ± 3 days after the last dose of study product; and

- Willing to follow instructions, complete study procedures and attend study visits as
required by this protocol.

Exclusion Criteria:

- Severe or unstable Systemic lupus erythematosus (SLE), such as any one of the
following:

- A British Isles Lupus Activity Group (BILAG) A score in one or more BILAG domains
at Screening;

- Treatment with any intraarticular, intravenous, or intramuscular systemic
corticosteroids within 14 days of Screening;

- Treatment with oral prednisone > 10 mg per day or > 20 mg every other day (or
equivalent dose of another corticosteroid) within 14 days of Screening;

- Increased dose of systemic corticosteroids in the 14 days prior to Screening;

- Treatment with cyclophosphamide or anti-TNFalpha biologic agents within 3 months
before Visit 1 (Day 1);

- Treatment with B cell-depleting monoclonal antibodies (rituximab, Ocrelizumab,
anti-CD22) within 6 months before Visit 1 (Day 1);

- Treatment with methotrexate, mycophenolate, azathioprine, leflunomide,
cyclosporine, belimumab, tacrolimus, or any other immunosuppressive agent not
included in 2b.-d. above, when the dose of that immunosuppressive agent has
increased within 3 months before Visit 1. Concurrent treatment with any of these
medications is allowed as long as the doses have been stable for at least 3
months before Visit 1 (Day 1); or

- Actively listed on an organ transplantation list or have received an organ
transplant other than a corneal transplant.

- Significant diseases or conditions other than SLE that may influence response to the
study product or safety, such as:

- Active bacterial or viral infection requiring systemic antibiotic or anti-viral
treatment within 14 days before Visit 1 (Day 1);

- Acute or chronic hepatitis B or C infection;

- Human immunodeficiency infection (HIV);

- History of active tuberculosis or positive tuberculosis skin or blood test
without: 1) completing a course of appropriate treatment; or ) having received at
least one month of appropriate treatment prior to Visit 1 (Day 1) and continuing
to receive appropriate treatment during the study;

- No elective surgery should be planned from Visit 1 (Day 1) through Visit 6 (Day
112); or

- A history of cancer except basal cell carcinoma or in situ carcinoma of the
cervix treated with apparent success with curative therapy greater than one year
before Visit 1 (Day 1).

- Significant heart disease as defined by:

- Uncontrollable congestive heart failure, unstable angina, unstable
atherosclerotic cardiovascular disease, significant arrhythmia requiring
chronic therapy, pulmonary arterial hypertension with dyspnea, disability
rated as New York heart Association Grade III or higher, severe systemic
hypertension or severe peripheral vascular disease;

- Marked baseline prolongation of QT/QTc interval (i.e. repeated demonstration
of a QTc interval ≥ 450 msec for males and ≥470 msec for females);

- History of risk factors for torsade de pointes (e.g., heart failure,
hypokalemia, family history of long QT/QTc syndrome); or

- Clinically significant confirmed abnormality, as determined by the site
investigator or qualified designee, on 12-lead Electrocardiogram (ECG) at
Screening or Visit 1 (Day 1) before dosing.

- History of chronic pain requiring treatment with narcotic analgesia for more than 14
days total within 6 months of baseline. This does not include self-limited pain
associated with identifiable events such as surgery;

- Current evidence of alcohol abuse (defined as 4 or more drinks per day on at least 4
days of the week) or history of abuse of illegal and/or legally prescribed drugs such
as barbiturates, benzodiazepines, amphetamines, cocaine, or opioids during the 1 year
prior to Screening;

- Currently pregnant, breast-feeding, or lactating;

- Any investigational agent within 30 days or five therapeutic half-lives of that agent
whichever is longer, before Visit 1 (Day 1);

- Any of the following values for laboratory tests at Screening:

- A positive pregnancy test (also at Visit 1);

- A newly positive QuantiFERON(R) blood test for tuberculosis, without: 1)
completing a course of appropriate treatment; or ) having received at least one
month of appropriate treatment prior to Visit 1 and continuing to receive
appropriate treatment during the study. If the subject has a previous documented
positive tuberculosis skin, then this testing does not need to be repeated. If
the subject has a documented negative test result within the last year, testing
does not need to be repeated, at the discretion of the site investigator.

- Hemoglobin < 8 g/dL;

- Neutrophils < 1.0 x 10^9/L;

- Platelets < 75 x 10^9/L;

- Estimated Glomerular Filtration Rate (eGFR) < 50 ml/min according to
Cockcroft-Gault equation;

- Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline
phosphatase > 2.0 x upper limit of normal; or

- Total bilirubin ≥ 1.5 x upper limit of normal.

- Any other conditions that, in the opinion of the site investigator, are clinically
significant and may put the subject at greater safety risk, influence response to
study product, or interfere with study assessments. When in doubt, the site
investigator or qualified designee should discuss the situation with the Protocol
Chairs.
We found this trial at
16
sites
1801 N Broad St
Philadelphia, Pennsylvania 19122
(215) 204-7000
Principal Investigator: Roberto Caricchio, MD
Phone: 856-304-9302
Temple University Temple University is many things to many people. A place to pursue life's...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Durham, North Carolina 27710
(919) 684-8111
Principal Investigator: Megan Clowse, MD
Phone: 919-684-6150
Duke University Younger than most other prestigious U.S. research universities, Duke University consistently ranks among...
?
mi
from
Durham, NC
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: S. Sam Lim, MD,MPH
Phone: 404-616-7553
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
1650 Grand Concourse
Bronx, New York 10457
Principal Investigator: Giovanni Franchin, MD
Phone: 718-960-1234
?
mi
from
Bronx, NY
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
843-792-1414
Principal Investigator: Diane Kamen, MD
Phone: 843-792-4296
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
?
mi
from
Charleston, SC
Click here to add this to my saved trials
2500 Metrohealth Dr
Cleveland, Ohio 44109
(216) 778-7800
Principal Investigator: Stanley Ballou, MD
Phone: 216-778-3309
MetroHealth Med Ctr The MetroHealth System is one of the largest, most comprehensive health care...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Hershey, Pennsylvania 17033
Principal Investigator: Nancy Olsen, MD
Phone: 717-531-0003
?
mi
from
Hershey, PA
Click here to add this to my saved trials
9500 Gilman Dr
La Jolla, California 92093
Principal Investigator: Kenneth Kalunian, MD
Phone: 858-246-2389
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
Los Angeles, California 90095
Principal Investigator: Maureen McMahon, MD
Phone: 310-825-6461
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
350 Community Drive
Manhasset, New York 11030
Principal Investigator: Meggan Mackay, MD, MS
Phone: 516-562-2591
?
mi
from
Manhasset, NY
Click here to add this to my saved trials
New Haven, Connecticut 6520
(203) 432-4771
Principal Investigator: Fotios Koumpouras, MD
Phone: 203-785-6631
Yale University Yale's roots can be traced back to the 1640s, when colonial clergymen led...
?
mi
from
New Haven, CT
Click here to add this to my saved trials
550 1st Avenue
New York, New York 10016
Principal Investigator: Amit Saxena, MD
Phone: 646-501-7387
?
mi
from
New York, NY
Click here to add this to my saved trials
161 Fort Washington Avenue
New York, New York 10032
Principal Investigator: Anca Askanase, MD
Phone: 212-342-1587
?
mi
from
New York, NY
Click here to add this to my saved trials
3451 Walnut St
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Principal Investigator: Steffan W Schulz, MD
Phone: 215-615-0773
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
3550 Terrace Street
Pittsburgh, Pennsylvania 15217
Principal Investigator: Ghaith Noaiseh, MD
Phone: 412-692-6516
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
400 Parnassus Avenue
San Francisco, California 94143
Principal Investigator: Maria Dall'Era, MD
Phone: 415-502-5108
?
mi
from
San Francisco, CA
Click here to add this to my saved trials